In This Article:
AbbVie stock edged higher Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.
AbbVie stock edged higher Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.